AAAAAA
Results:
1-8
|
Results: 8
Authors:
Hawkey, CJ
Jackson, L
Harper, SE
Simon, TJ
Mortensen, E
Lines, CR
Citation: Cj. Hawkey et al., The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans, ALIM PHARM, 15(1), 2001, pp. 1-9
Authors:
Peterson, SA
Simon, TJ
Citation: Sa. Peterson et Tj. Simon, Computational evidence for the subitizing phenomenon as an emergent property of the human cognitive architecture, COGN SCI, 24(1), 2000, pp. 93-122
Authors:
Watson, DJ
Harper, SE
Zhao, PL
Quan, H
Bolognese, JA
Simon, TJ
Citation: Dj. Watson et al., Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis, ARCH IN MED, 160(19), 2000, pp. 2998-3003
Authors:
Hunt, RH
Bowen, B
Mortensen, ER
Simon, TJ
James, C
Cagliola, A
Quan, H
Bolognese, JA
Citation: Rh. Hunt et al., A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects, AM J MED, 109(3), 2000, pp. 201-206
Authors:
Simon, TJ
Citation: Tj. Simon, The foundations of numerical thinking in a brain without numbers, TRENDS C SC, 3(10), 1999, pp. 363-365
Authors:
Sathian, K
Simon, TJ
Peterson, S
Patel, GA
Hoffman, JM
Grafton, ST
Citation: K. Sathian et al., Neural evidence linking visual object enumeration and attention, J COGN NEUR, 11(1), 1999, pp. 36-51
Authors:
Lanza, FL
Rack, MF
Simon, TJ
Quan, H
Bolognese, JA
Hoover, ME
Wilson, FR
Harper, SE
Citation: Fl. Lanza et al., Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen, ALIM PHARM, 13(6), 1999, pp. 761-767
Authors:
Langman, MJ
Jensen, DM
Watson, DJ
Harper, SE
Zhao, PL
Quan, H
Bolognese, JA
Simon, TJ
Citation: Mj. Langman et al., Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs, J AM MED A, 282(20), 1999, pp. 1929-1933
Risultati:
1-8
|